GTEC Focus on Hepatitis B – There is Huge Demand
WHO and UNICEF Are Helping China Battle Cause of Deadly Liver Cancer, Achieving Dramatic Increase in Delivery of Vaccines to Most Remote Provinces
WHO and UNICEF Are Helping China Battle Cause of Deadly Liver Cancer, Achieving Dramatic Increase in Delivery of Vaccines to Most Remote Provinces
Currently, Genesis owns 8.5 million shares in Gold Horse International and 6.7 million shares in Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. has advanced in the development of a treatment for Hepatitis B and also increased its number of local outlets to 15 retail stores. Hepatitis B infections are a huge problem in Asia and China. China has begun to address the issue with massive immunizations but many countries lag behind.
China recently immunized millions of children against Hepatitis B in an historic collaboration with the GAVI Alliance.
China has immunized 11.1 million children in the country’s poorest and most remote western and central provinces against hepatitis B, reducing their risk of developing a deadly and common liver cancer, noted the Chinese government and the GAVI Alliance.
Chinese health officials have directed their efforts toward boosting immunizations which represent a 60 percent increase in hepatitis B vaccine doses delivered to children in targeted provinces. The children reached include newborns, who receive a ”birth dose” of vaccine plus two more doses at one and six months of age, as well as previously unvaccinated children under five, who must also receive a full three-dose vaccine series.
China’s goal is to protect all the babies at birth from this virus and the China-GAVI Hepatitis B Immunization Project has propelled China into the modern age of immunizations covering one-third of all children born in China since the project began in 2002.
According to an estimate based on a 1992 national hepatitis epidemiological survey, 120 million people in China are chronically infected with hepatitis B (HepB). Those infected are at risk of liver cancer or failure, and can spread the disease to others. In the western provinces, the campaign, with technical guidance from the World Health Organization (WHO) and UNICEF, has reached almost 70 percent of newborns with a birth dose of vaccine in 2005, up from 47 percent in 2002. Newborns are a key target of the effort, since vaccination within the first 24 hours of life is the only way to protect an infant from transfer of virus from an infected mother.
Since its inception, the campaign has averted over 200,000 future deaths due to the chronic consequences of hepatitis B, mainly from cancer of the liver and cirrhosis. Death typically comes decades after children are exposed to the virus during childbirth or in their first years of life.
The breakthrough is the result of a five-year US$76 million project, co- funded equally by the Government of China and the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunization). Known as the China Ministry of Health/GAVI Hepatitis B Vaccination Project, the GAVI-supported campaign has targeted newborns and children under five across an area that encompasses 470 million people, including six million newborns every year. It has reached babies born in hospitals, as well as those born at home in mountain villages or in the tents of nomadic herders on the vast steppes.
China’s success is a model for other countries still struggling to stop the spread of the hepatitis B virus and other vaccine-preventable diseases.”
According to preliminary data, provincial governments have added to the funds provided by GAVI and the central government, contributing more than US$10 million in co-payments. Lob-Levyt noted as well that the support of the World Health Organization (WHO) and UNICEF has been critical.
Worldwide, GAVI’s support has made it possible to immunize 90 million children against hepatitis B and avert an estimated 1.4 million deaths from this disease alone.
WHO and UNICEF are among the GAVI partners and other key immunization groups(*) in China that support the China National Immunization Programme efforts to reach all children with life-saving vaccines and technologies, as well as with polio eradication, measles control, and new vaccine introduction. WHO and UNICEF have supported the development and implementation of the China- GAVI project, through the national Interagency Coordinating Committee and project Operations Advisory Group.
GAVI’s efforts are critical to achieving the Millennium Development Goal on child health, which calls for reducing childhood mortality by two-thirds by 2015. Of the more than 10 million children who die before reaching their fifth birthday every year, 2.5 million die from diseases that could be prevented with currently available or new vaccines. Since 2000, the catalyzing efforts of the GAVI Alliance have ensured that 90 million children in the world’s poorest countries were immunized against hepatitis B.
Demand for Vaccine Enormous
About three-quarters of the 1301 project counties have reached the target of 85 percent of children receiving the complete HepB vaccine series, and half have reached the timely birth dose target. However, over one million babies born each year in GAVI project counties are still not receiving a timely birth dose.
In the project’s final years, it will concentrate on achieving those targets in every county, both through reaching more babies born at home and by waging a ”catch-up” campaign to reach still unvaccinated children. The project will also focus on enhancing injection safety through wider use of AD syringes, and will encourage the expanded use of AD syringes for all immunizations given in China.
”Finally, long-term success depends on assuring that no new financial barriers arise to block HepB immunization in the future,” Lob-Levyt said. ”This is one of the greatest challenges, and the solution lies not just within China, but with a global community mobilized to ensure access to vaccine financing for all developing nations.”
The GAVI Alliance Support Hepatitis B Vaccine
An alliance of all the major stakeholders in immunization, the GAVI Alliance includes among its partners developing country and donor governments, the World Health Organization (WHO), UNICEF, the World Bank, the vaccine industry in both industrialized and developing countries, research and technical agencies, NGOs, and the Bill & Melinda Gates Foundation. It is estimated that more than 1.7 million early deaths will have been prevented as a result of support by GAVI up to the end of 2005.
GAVI’s efforts are critical to achieving the Millennium Development Goal on child health, which calls for reducing childhood mortality by two-thirds by 2015. Of the more than 10 million children who die before reaching their fifth birthday every year, 2.5 million die from diseases that could be prevented with currently available or new vaccines.
Lotus, Inc. is well established in China in R&D for Hepatitis B. While Genesis works on the treatment, its retail pharmacies are quickly becoming established and generating revenue for the R&D arm of the company! This is a clever way to finance the Research and Development demands for a new medical treatment.
GTEC has with this combination of companies demonstrated its very focused approach to cash flow and revenue!
SOURCES World Health Organization – GAVI – WHO China – UNICEF China
Genesis Technology Group, Inc. Boca Corporate Plaza
7900 Glades Road, Suite 420
Boca Raton, FL 33434
Phone: (561) 988-9880
Fax: (561) 988-9890
Email: General Information: info@genesis-china.net
Investor relations: clinton@genesis-china.net
Disclosure: Pentony Enterprises LLC has been compensated $3,600 and 265,000 restricted shares directly from the company for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.
Forward Looking Statement: Certain sections of this report may contains forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, aircraft production, deliveries and backlog stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors, including, without limitation:
General and international political and economic conditions; All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.
